Nitroheterocycle Reduction as a Paradigm for Intramolecular Catalysis of Drug Delivery to Hypoxic Cells

Journal of Medicinal Chemistry

Volumn 34, Issue 9, 1991, Pages 2933-2935

  Firestone, Albert ^a   Borch, Richard F ^a   Mulcahy, R Timothy ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; MELPHALAN; PHOSPHORAMIDE MUSTARD [3 ETHOXY 1 (6 METHYLAMINO 3 NITRO 8 QUINOLYL) 3 OXOPROPYL] ESTER; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHORIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; BONE MARROW CELL; COLON CANCER; CYTOTOXICITY; DNA CROSS LINKING; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; LETTER; MOUSE; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW CELLS; CATALYSIS; CELL SURVIVAL; CELLS, CULTURED; COLONIC NEOPLASMS; HUMAN; NITROGEN; NITROQUINOLINES; OXIDATION-REDUCTION; OXYGEN; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; VEHICLES;

EID: 0025951037     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00113a040     Document Type: Article

References (16)

1. Sartorelli, A. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res. 1988, 48, 775-778.
2. Biochem. Pharmacol. 1986, 35, 1-122.
3. Stratford, I. J.; O’Neill, P.; Sheldon, P. W.; Silver, A. R. J.; Walling, J. M.; Adams, G. E. RSU 1069, a nitroimidazole containing an aziridine group. Biochem. Pharmacol. 1986, 35, 105-109.
4. +) human tumor cells. Cancer Res. 1988, 48, 798-801.
5. Kirkpatrick, D. L. The development of hypoxic tumor cell cytotoxic agents. Pharmacol. Ther. 1989, 40, 383-399.
6. Denny, W. A.; Atwell, G. J.; Anderson, R. F.; Wilson, W. R. Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: The “iminoacridan hypothesis”. J. Med. Chem. 1990, 33, 1288-1295.
7. Borch, R. F.; Millard, J. A. The mechanism of activation of 4-hydroxycyclophosphamide. J. Med. Chem. 1987, 30, 427-431.
8. 31P NMR evidence for equilibration of ctsand trtms-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution. J. Med. Chem. 1984, 27, 490-494.
9. Kwon, C.-H.; Borch, R. F. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues. J. Med. Chem. 1989, 32, 1491-1496.
10. Spencer, A. A highly efficient version of the palladium-catalysed arylation of alkenes with aryl bromides. J. Organomet. Chem. 1983, 258, 101-108.
11. Kita, Y.; Segawa, J.; Haruta, J.; Yasuda, H.; Tamura, Y. Ketene silyl acetal chemistry; simple synthesis of methyl jasmonate and related compounds by utilising ketene methyl dimethyl-t-butylsilyl acetal. J. Chem. Soc. Perkin Trans. 1 1982, 1099-1104.
12. Bradley, D. C. Thallous íerí-amyloxide. J. Chem. Soc. 1958, 4780-4781.
13. Jacobsen, E. N.; Marko, I.; Mungall, W. S.; Schroder, G.; Sharpless, K. B. Asymmetric dihydroxylation via ligand-accelerated catalysis. J. Am. Chem. Soc. 1988, 110, 1968-1970.
14. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
15. +) and deficient (Mer”) cell lines. Cancer Res. 1986, 46, 2892-2897.
16. Kohn, F. R.; Sladek, N. E. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem. Pharmacol. 1985, 34, 3465-3470.